Tildrakizumab

Drug Profile

Tildrakizumab

Alternative Names: Anti-IL-23p19 monoclonal antibody; MK-3222; SCH-900222

Latest Information Update: 15 Dec 2016

Price : $50

At a glance

  • Originator Schering-Plough
  • Developer Merck & Co; Schering-Plough
  • Class Antipsoriatics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Interleukin-23 subunit p19 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Plaque psoriasis
  • Discontinued Autoimmune disorders

Most Recent Events

  • 07 Nov 2016 Almirall announces intention to submit MAA to EMA in the second quarter of 2017
  • 01 Oct 2016 Adverse events and efficacy data from phase III trials reSURFACE 1 and reSURFACE 2 in Plaque psoriasis released by Sun Pharma
  • 27 Jul 2016 Sun Pharma enters into licensing agreement with Almirall for the development and commercialisation of tildrakizumab in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top